The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target.
Authors | |
Keywords | |
Abstract | Our hypothesis is that changes in gene and protein expression are crucial to the development of late-onset Alzheimer’s disease. Previously we examined how DNA alleles control downstream expression of RNA transcripts and how those relationships are changed in late-onset Alzheimer’s disease. We have now examined how proteins are incorporated into networks in two separate series and evaluated our outputs in two different cell lines. Our pipeline included the following steps: (i) predicting expression quantitative trait loci; (ii) determining differential expression; (iii) analysing networks of transcript and peptide relationships; and (iv) validating effects in two separate cell lines. We performed all our analysis in two separate brain series to validate effects. Our two series included 345 samples in the first set (177 controls, 168 cases; age range 65–105; 58% female; KRONOSII cohort) and 409 samples in the replicate set (153 controls, 141 cases, 115 mild cognitive impairment; age range 66–107; 63% female; RUSH cohort). Our top target is heat shock protein family A member 2 (HSPA2), which was identified as a key driver in our two datasets. HSPA2 was validated in two cell lines, with overexpression driving further elevation of amyloid-β40 and amyloid-β42 levels in APP mutant cells, as well as significant elevation of microtubule associated protein tau and phosphorylated-tau in a modified neuroglioma line. This work further demonstrates that studying changes in gene and protein expression is crucial to understanding late onset disease and further nominates HSPA2 as a specific key regulator of late-onset Alzheimer’s disease processes.10.1093/brain/awy215_video1awy215media15824729224001. |
Year of Publication | 2018
|
Journal | Brain
|
Volume | 141
|
Issue | 9
|
Pages | 2721-2739
|
Date Published | 2018 09 01
|
ISSN | 1460-2156
|
DOI | 10.1093/brain/awy215
|
PubMed ID | 30137212
|
PubMed Central ID | PMC6136080
|
Links | |
Grant list | RF1 AG015819 / AG / NIA NIH HHS / United States
G1100540 / MRC_ / Medical Research Council / United Kingdom
P50 AG005128 / AG / NIA NIH HHS / United States
P50 AG005146 / AG / NIA NIH HHS / United States
P30 AG010161 / AG / NIA NIH HHS / United States
G0400074 / MRC_ / Medical Research Council / United Kingdom
P50 AG005144 / AG / NIA NIH HHS / United States
P30 AG053760 / AG / NIA NIH HHS / United States
P50 MH060451 / MH / NIMH NIH HHS / United States
P41 GM103493 / GM / NIGMS NIH HHS / United States
U01 AG016976 / AG / NIA NIH HHS / United States
P50 NS039764 / NS / NINDS NIH HHS / United States
P50 AG005681 / AG / NIA NIH HHS / United States
P30 AG013846 / AG / NIA NIH HHS / United States
R01 AG017917 / AG / NIA NIH HHS / United States
P50 AG005136 / AG / NIA NIH HHS / United States
G0900652 / MRC_ / Medical Research Council / United Kingdom
P50 AG016570 / AG / NIA NIH HHS / United States
P50 AG005134 / AG / NIA NIH HHS / United States
G0502157 / MRC_ / Medical Research Council / United Kingdom
R01 AG034504 / AG / NIA NIH HHS / United States
R01 AG041232 / AG / NIA NIH HHS / United States
P30 AG019610 / AG / NIA NIH HHS / United States
RF1 AG057457 / AG / NIA NIH HHS / United States
|